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Abstract 26 
Interleukin 33 (IL-33), which is expressed by several immune cell types, endothelial and 27 
epithelial cells, and fibroblasts, is a cytokine of the IL-1 family that acts both intra- and 28 
extracellularly to either enhance or resolve the inflammatory response.  Intracellular IL-33 acts 29 
in the nucleus as a regulator of transcription. Once released from cells by mechanical stress, 30 
inflammatory cytokines, or necrosis, extracellular IL-33 is proteolytically processed to act in an 31 
autocrine/paracrine manner as an “alarmin” on neighboring or various immune cells expressing 32 
the ST2 receptor. Thus, IL-33 may serve an important role in tissue preservation and repair in 33 
response to injury; however, the actions of IL-33 are dampened by a soluble form of ST2 (sST2) 34 
that acts as a decoy receptor and is produced by endothelial and certain immune cells. 35 
Accumulating evidence supports the conclusion that sST2 is a biomarker of vascular health with 36 
diagnostic and/or prognostic value in various cardiovascular diseases, including coronary artery 37 
disease, myocardial infarction, atherosclerosis, giant-cell arteritis, acute aortic dissection, and 38 
ischemic stroke, as well as obesity and diabetes. Although sST2 levels are positively associated 39 
with cardiovascular disease severity, the assumption that IL-33 is always beneficial is naïve. It is 40 
increasingly appreciated that the pathophysiological importance of IL-33 is highly dependent on 41 
cellular and temporal expression. Although IL-33 is atheroprotective and may prevent obesity 42 
and type 2 diabetes by regulating lipid metabolism, IL-33 appears to drive endothelial 43 
inflammation. Here, we review the current knowledge of the IL-33/ST2/sST2 signaling network 44 
and discuss its pathophysiological and translational implications in cardiovascular diseases. 45 
 46 
 47 
 48 
  49 
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Introduction 50 
Interleukin 33 (IL-33) is a member of the IL-1 family of cytokines, which strongly induces 51 
production of T helper-2 (Th2)-associated cytokines. Although regulation of transcription has 52 
been recently reported as an additional mechanism of IL-33 activity (see Novel signaling), 53 
classically active IL-33 functions as an “alarmin” or stress-response cytokine that engages and 54 
regulates an immune response particularly at barrier sites in the body, where IL-33 is highly 55 
expressed by endothelial or epithelial cells.1   Once released, IL-33 acts in an 56 
autocrine/paracrine manner to activate the ST2L (ST2 gene-like) membrane receptor on nearby 57 
cells, aka IL33R and interleukin 1 receptor like 1 (IL1RL1). A soluble truncated form of ST2L 58 
without the transmembrane and intracellular domains, sST2, is secreted by endothelial and 59 
various immune cells either constitutively or upon stimulation (in some cases by IL-33).2 sST2 is 60 
thought to function as a decoy receptor, thereby attenuating the actions of IL-33.2  61 
Evidence over the last decade has supported the conclusion that the sST2/ST2L/IL-33 62 
triad plays an important role in CVD. IL-33 is postulated to exert for the most part beneficial 63 
actions via ST2L that are related to cardiac repair or attenuation of adverse cardiovascular 64 
remodeling or atherosclerotic plaque progression. In the canonical model, sST2 attenuates the 65 
cellular and beneficial actions of IL-33 in the cardiovascular system. Accumulating evidence has 66 
shown that elevated circulating levels of sST2 have evident prognostic utility for worse outcome 67 
in acute myocardial infarction (MI),3 systemic and pulmonary hypertension,4-6 coronary artery 68 
disease (CAD),7 heart failure,8  and type 2 diabetes.9, 10  Most often, sST2, and not IL-33, was 69 
assessed due to its greater levels and stability.  70 
  New findings reveal that this view of IL-33 as strictly a protective or benign agent in 71 
CVD is over-simplistic. Neither is it established that sST2 is harmful because of its role as decoy 72 
receptor. As we assess in this review article, notwithstanding the evidence supporting the utility 73 
of sST2 as a CVD biomarker, there are gaps in our understanding of the functional significance 74 
of the IL-33/sST2 axis in cardiovascular and metabolic stress. Specifically, the focus of this 75 
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review is on the vascular and metabolic aspects of the sST2/ST2L/IL-33 triad as a diagnostic 76 
and prognostic biomarker of stable CAD, MI, atherosclerosis, stroke, obesity, and type 2 77 
diabetes. Also, we address the complicated question of whether IL-33/ST2 signaling functions 78 
simply as an acute “alarmin” system or contributes to CVD progression under chronic or 79 
dysregulated conditions. In that context, the involvement of various immune cells and novel 80 
intracellular and extracellular signaling mechanisms in the actions of IL-33 are discussed.  81 
 82 
Cellular expression  83 
The membrane receptor for IL-33, ST2L is highly expressed by a wide variety of immune 84 
cells, including Th2 cells, regulatory T cells (Tregs), M2 polarized macrophages, mast cells, 85 
eosinophils, basophils, natural killer (NK) cells, invariant natural killer T (iNKT) cells, and type 2 86 
innate lymphoid cells (ILC2s).2 ST2L is constitutively expressed on cells of the cardiovascular 87 
system, in particular endothelial cells,11  and can also be transiently induced in certain cases in 88 
other immune cell types, such as Th1 and cytotoxic T cells.12 The notable actions of IL-33 on 89 
various immune cells are summarized in Table 1. In general, IL-33 is an important player in both 90 
innate and adaptive immunity as ST2L is expressed on most immune cells. By activating Th2 91 
cells, IL-33 elicits a type 2 immune response, particularly at barrier sites. IL-33 also exerts 92 
protective and anti-inflammatory effects involving Treg and ILC2 (see Mechanistic insights 93 
into the role of IL-33/sST2 in atherosclerosis and Obesity and type 2 diabetes). However, if 94 
exuberant or dysregulated, type 2 inflammation may lead to tissue damage likely through 95 
activation of mast cells or eosinophils, and the development of pathological fibrosis.13 In this 96 
way, IL-33 plays an indirect role in the pathophysiology of several pro-inflammatory and auto-97 
immune diseases including asthma, allergies, arthritis, sepsis, and inflammatory bowel 98 
disease.14  Whether a similar scenario also occurs in CVD is not known, and in fact the immune 99 
cell-specific role of IL-33 in CVD is not yet defined. 100 
 101 
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Table 1. Principal immune cells responsive to IL-33 102 
 103 
In healthy human tissues, IL-33 is mainly expressed by stromal cells, including 104 
endothelial and epithelial cells, and specialized fibroblasts.53  IL-33 is constitutively present in 105 
the nuclei of cardiac fibroblasts, cardiac endothelial cells, cardiomyocytes, and coronary artery 106 
smooth muscle cells of human adults and is released during stress or with necrosis.11 It is 107 
expressed only to a limited extent in mouse endothelial cells.54 IL-33 can also be released from 108 
Immune	  Cell	  Type	   Action	  
	  
B	  Cells	  
	  
• Increases	  circulating	  IL-­‐10-­‐producing	  B	  cells15	  
• Enhances	  proliferation	  capacity	  of	  B1	  B	  cells	  and	  IgM,	  IL-­‐5,	  and	  IL-­‐13	  production16	  
Basophils	   • Promotes	  secretion	  of	  type	  2	  cytokines	  (e.g.	  IL-­‐4	  and	  IL-­‐13)	  and	  IL-­‐8	  in	  synergy	  
with	  IL-­‐3	  and/or	  FcεRI-­‐activation,	  and	  enhances	  FcεRI-­‐induced	  mediator	  release17	  	  
• Prevents	  sST2	  release,	  which	  is	  induced	  by	  IL-­‐3	  and	  C5a	  or	  anti-­‐FcεRIα	  antibody	  17	  
Dendritic	  cells	  (DC)	   • Increases	  surface	  levels	  of	  maturation	  markers	  MHC-­‐II,	  CD40,	  CD80,	  CD86,	  
OX40L,	  and	  CCR718-­‐20	  	  
• Increases	  production	  of	  pro-­‐allergic	  cytokines	  and	  chemokines	  IL-­‐4,	  IL-­‐5,	  IL-­‐13,	  
CCL17,	  TNF-­‐α,	  and	  IL-­‐1β19	  	  
• IL-­‐33-­‐activated	  murine	  DCs	  required	  for	  in	  vitro	  and	  in	  vivo	  expansion	  of	  ST2+	  
Tregs	  due	  to	  IL-­‐2	  production21	  	  
• IL-­‐33-­‐activated	  DCs	  prime	  naive	  lymphocytes	  to	  produce	  the	  Th2	  cytokines	  IL-­‐5	  
and	  IL-­‐13,	  but	  not	  IL-­‐4	  and	  IFN-­‐γ18,	  20	  
Eosinophils	   • Regulates	  homeostatic	  development	  and	  activation	  during	  disease22	  	  
• Enhances	  adhesion,	  CD11b	  expression	  and	  survival23	  	  
• Induces	  superoxide	  anion	  production,	  degranulation,	  and	  IL-­‐8	  production24	  	  
• Exacerbates	  eosinophil-­‐mediated	  airway	  inflammation	  (increases	  IL-­‐13,	  TGF-­‐β,	  
CCL3,	  CCL17,	  and	  CCL24)25	  	  
• Enhances	  Siglec-­‐8	  mediated	  apoptosis26	  
ILC2	   • Promotes	  type	  2	  cytokines	  production27,	  28	  	  
• Expands	  in	  vivo27,	  29	  
Invariant	  natural	  
killer	  T	  
(iNKT)	  
• Causes	  expansion	  and	  activation30	  	  
• Enhances	  production	  of	  several	  cytokines,	  including	  both	  IL-­‐4	  and	  IFN-­‐γ	  and	  
induces	  IFN-­‐γ	  instead	  of	  IL-­‐4	  upon	  TCR	  engagement	  in	  cooperation	  with	  IL-­‐1230,	  31	  	  
M2	  polarized	  
macrophages	  
• Amplifies	  the	  expression	  of	  M2	  markers32,	  33	  	  	  
• Enhances	  activation	  by	  upregulating	  LPS	  receptor	  components	  TLR4	  and	  MD2,	  
soluble	  CD14,	  and	  MyD88,	  thus	  increasing	  LPS-­‐induced	  cytokine	  production33	  	  
Mast	  cells	   • Induces	  production	  of	  inflammatory	  cytokines	  MCP-­‐1,	  TNF-­‐α,	  IL-­‐1,	  and	  	  IL-­‐634	  
• Enhances	  IgE-­‐mediated	  activation34	  	  
• Promotes	  survival35,	  36	  
• Promotes	  mast	  cell	  activation	  and	  maturation,	  and	  induces	  GM-­‐CSF,	  IL-­‐5,	  IL-­‐13,	  
CXCL8,	  CCL17,	  CCL22,	  and	  CCL2	  secretions36,	  37	  	  
• Induces	  production	  of	  various	  type	  2	  cytokines38-­‐40	  	  
• Promotes	  Th17	  response	  during	  airway	  inflammation41	  	  
Natural	  killer	  (NK)	  
cells	  
• Increases	  IFN-­‐γ	  synergistically	  with	  IL-­‐1230,	  31	  	  
Regulatory	  T	  cells	  
(Treg)	  
• Enhances	  protective	  ability/increases	  immunomodulatory	  function42,	  43	  	  
• Expands/increases	  directly	  or	  via	  IL-­‐33-­‐induced	  DC	  production	  of	  IL-­‐221,	  44-­‐50)	  	  
Th2	  cells	   • Increases	  production	  of	  type	  2	  cytokines	  IL-­‐5	  and	  IL-­‐1351	  	  	  
• Chemoattractant52	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cells as a consequence of the cleavage of membrane phospholipids by secreted phospholipid 109 
A2 (sPLA2) enzymes, which is relevant to how venoms and inhaled allergens elicit a type 2 110 
immune response55 and likely relevant to atherosclerosis as well. In addition, IL-33 is a 111 
mechanically responsive cytokine secreted by living cells in response to stretch (Fig. 1).56 Pro-112 
inflammatory cytokines such as TNF-α, IFN-γ, and IL-1β increase IL-33 expression.11  113 
In humans, ST2L and sST2 mRNA on the other hand were reported to be expressed at 114 
low levels in cardiomyocytes, cardiac fibroblasts, and vascular smooth muscle cells, but widely 115 
present in endothelial cells of the cardiac vasculature.11 ST2L is prominently expressed by 116 
ILC2s, mast cells, and Tregs expressing the GATA3 transcription factor, as well as by activated 117 
Th2 lymphocytes.2 Levels of ST2L are enhanced by IL-33 in ILC2s and Tregs, but neither 118 
expresses sST2. ST2L is expressed weakly as well by dendritic cells, neutrophils, and 119 
uncommitted macrophages (and enhanced by IL-4/IL-13).2  120 
Taken together these findings would suggest that the primary direction for 121 
communication of the IL-33 alarmin system is from parenchyma or endothelium to the 122 
endothelium and immune cells, with production of sST2 by endothelial cells and certain pro-123 
inflammatory immune cells serving a protective or damping role. Uncertain, however, is how 124 
ST2L expression in cardiovascular cells is affected by disease state.  125 
  126 
Novel signaling  127 
Two modes of action have been identified for IL-33, an extracellular one as a cytokine or 128 
alarmin, and a nuclear one as a regulator of transcription. Pro- and anti-inflammatory actions 129 
have been attributed to both modes of action, which are cell- and context-dependent. IL-33 130 
localizes to the nucleus due to the presence of two bipartite nuclear localization sequences in 131 
the predicted helix-turn-helix structure of the homeodomain-like N-terminus.57 Deubiquitination 132 
of IL-33 has been implicated in its nuclear stability, yet ubiquitination of IL-33 has also been 133 
implicated in its activation of transcription.58, 59 A better understanding of the different 134 
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ubiquitination profiles of IL-33 and their significance is needed.  135 
IL-33 associates with chromatin to ostensibly repress gene expression via protein-136 
protein interactions, involving a short chromatin-binding motif that binds the acidic pocket made 137 
by the histone heterodimer H2A-H2B at the nucleosome surface.60 However, the nuclear actions 138 
of IL-33 are diverse and incompletely understood. Binding of IL-33 to promoter-bound 139 
homeodomain proteins, such as histone methyltransferase SUV39/HI, was implicated in IL-33-140 
mediated suppression of IL-6 and sST2 expression in human atrial endothelial cells.61 IL-33 was 141 
reported to induce transcription of the type 2 inflammatory cytokine IL-13 in HEK293T cells by 142 
binding a conserved noncoding sequence before the transcription initiation site.58 In addition, IL-143 
33 was reported to function as a transcriptional regulator of NF-κB p65 expression in endothelial 144 
cells and participate in the inflammatory response by binding the p65 promoter.62 In contrast, IL-145 
33 was reported to act as a transcriptional repressor of NF-κB in synoviocytes of patients with 146 
rheumatoid arthritis.63 In some cases, IL-33/NF-κB p65 protein–protein interactions may impair 147 
NF-κB DNA binding and thus interfere with NF-κB-dependent transcription.64 Thus, both pro- 148 
and anti-inflammatory actions have been ascribed to nuclear IL-33.65, 66 However, in many cell 149 
types, the role of nuclear IL33 is still unknown.67  150 
IL-33 is constitutively expressed in many non-hematopoietic tissues, but its expression 151 
can be induced in both non-hematopoietic and some hematopoietic cells.2, 60 Th1 and Th2 152 
cytokines were reported to regulate intracellular levels of the precursor or full-length IL-33 in 153 
fibroblasts of healthy human lungs by activating or inhibiting, respectively, its proteasomal 154 
degradation.68 Notably, full-length IL-33 was found to promote inflammation in the lung, but not 155 
a Th2 response, in an ST2-independent fashion.69 Importin-5 (IPO5) was identified as an 156 
intracellular binding partner of full-length IL-33 that protects it from proteasomal degradation, but 157 
IPO5 is not required for nuclear localization of IL-33 and does not control its secretion.70  158 
Full-length IL-33 is released into the extracellular space on cell damage or necrosis, 159 
whereas caspases 3 and 7 cleave and inactivate intracellular IL-33 during apoptosis (Fig. 1).71 160 
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Alternative transcript splicing with deletion of exons 3 and 4 may confer cytoplasmic localization 161 
and facilitate secretion.72 The release of IL-33 from cells in the absence of damage or necrosis 162 
is not well understood, but in bronchial epithelial cells was shown to be under the regulation of 163 
ATP-induced P2 purinergic receptor stimulation and calcium influx.73  164 
Extracellular IL-33 activates the membrane receptor ST2L, which together with the co-165 
receptor IL-1R accessory protein (IL-1RAcP) recruits MYD88, IRAK1, IRAK4, and TRAF6, 166 
followed by activation of multiple signaling pathways, including MAPK1/ERK2 and/or 167 
MAPK3/ERK1, p38α MAPK, JNK1, and NF-κB (Fig. 2).60 An extensive quantitative 168 
phosphoproteomic analysis of IL-33-mediated signaling was recently reported.74 There is 169 
evidence as well that extracellular IL-33 may suppress activation of the p38 MAPK and NF-κB 170 
pathways in the heart 3 days post-MI, but this is likely indirect.75 A number of mechanisms act to 171 
localize and limit both temporally and spatially the actions of extracellular IL-33 so as to make 172 
less likely an uncontrolled Th2 inflammatory response. Unlike most IL-1 family members, IL-33 173 
has a comparatively long pro-peptide sequence of ~110 amino acid residues at the N-terminus. 174 
Contrary to original thinking, IL-33 bioactivation does not seem to be dependent upon 175 
caspase1/inflammasome-mediated processing within the cell, nor is cleavage necessary for 176 
secretion.76, 77 Rather, a number of extracellular proteases are involved in its activation, with the 177 
cleaved sequence targeted within the N-terminal domain or central domain being protease-178 
specific.71 These include proteases that are released by neutrophils and mast cells, such as 179 
neutrophil proteinase 3 (PR3), elastase, and cathepsin G. Moreover, it was recently proposed 180 
that full-length IL-33 functions as a biochemical sensor of the proteolytic activities of a large 181 
variety of environmental aeroallergens.78  182 
While short term exposure enhances the activity of IL-33, longer exposure to some 183 
proteases promotes further degradation and loss of activity by targeting the C-terminus IL-1-like 184 
cytokine domain. Furthermore, IL-33 is also rapidly oxidized within the extracellular milieu 185 
resulting in the formation of two intramolecular disulfide bonds that disrupt the ST2L binding 186 
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site.79  Besides impairing function, IL-33 oxidation might alter its immunoreactivity and confound 187 
assays that rely on antibody detection. Thus, oxidation should be taken into consideration in 188 
measuring IL-33 especially under conditions of heightened inflammation and oxidative stress, as 189 
seen for instance with cigarette smoke, a major CVD risk factor.80, 81      190 
In the canonical model, sST2 functions as a decoy receptor for IL-33, thereby preventing 191 
the cellular actions of IL-33 mediated by interaction with the membrane receptor ST2L (Fig. 2). 192 
However, there are a few intriguing reports that sST2 may have actions of its own on certain 193 
cells. Evidence was reported that sST2 has direct anti-inflammatory actions on macrophages by 194 
downregulating Toll-like receptors. Treatment with an ST2-human IgG fusion protein induced 195 
cellular signaling and down-regulated expression of TLR4 and TLR1 in bone marrow-derived 196 
macrophages.82 In addition, administration of the fusion protein to mice attenuated LPS-197 
mediated mortality and serum levels of IL-6, IL-12, and TNF-α, while an anti-ST2 antibody 198 
worsened the toxic effects of LPS, which are known to be mediated by TLR4. Others reported 199 
that sST2 suppresses LPS-induced IL-6 production in a human monocytic leukemia cell line.83 200 
Evidence (based on an ST2 Fc chimera protein) was also reported to support the conclusion 201 
that sST2 may contribute to adverse aortic remodeling seen in obesity by stimulating VSMCs to 202 
produce collagen type I, fibronectin, and profibrotic factors, as well as increase activities of 203 
MMPs.84 Note, however, that because of the IgG portion of the molecule, sST2-fusion proteins 204 
(unlike sST2) could theoretically undergo dimerization, which might impact on their actions. 205 
 206 
IL-33 and sST2 as biomarkers in coronary artery disease and myocardial infarction  207 
The results of several studies summarized in Table 2 support the conclusion that serum 208 
levels of IL-33 decrease with increasing CVD severity.85-87 The opposite pattern was reported for 209 
either the pro-inflammatory cytokine IL-6 or the extracellular protease matrix metalloproteinase 210 
(MMP)-28,85-87 supporting the proposal that combining their assessment with that of IL-33 might 211 
be useful in gauging the severity of CAD. However, the number of CAD/ACS cases were small 212 
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in these 3 studies (n = 83/40, 103/27, and 70/20). Others did not find a difference in IL-33 213 
between patients with ACS (n = 195) and stable CAD (n = 178), but in this study the highest 214 
quintile of IL-33 predicted mortality (mean follow-up 3.6 years) in patients with STEMI.88 215 
Although the number of participants was larger, it was still relatively small and the number of 216 
patients with adverse clinical events at follow-up was very small (37 deaths). Moreover, serum 217 
IL-33 was undetectable in more than 50% of study participants. Accurate assessment of IL-33 in 218 
human serum is difficult for a number of reasons, including lack of sensitivity and specificity of 219 
available ELISA assays, interference by the presence of sST2, and the use of non-serum 220 
certified kits.89 There is also a necessity to differentiate between oxidized (inactive) and reduced 221 
(active) forms of IL-33, which is now possible through the development of specific ELISAs.79  222 
In contrast, a clear pattern of increasing serum sST2 levels with greater severity of CAD 223 
events has been consistently observed (healthy < stable angina < unstable angina < non-ST 224 
elevation MI (NSTEMI) < STEMI < sudden cardiac death).  Several studies have reported the 225 
prognostic value of sST2 in patients with stable CAD.  In the Ludwigshafen risk and 226 
cardiovascular health study, sST2 did not correlate with the angiographic severity of CAD; 227 
however, on long-term follow-up (median time of 9.8 years), higher levels of sST2 were an 228 
independent predictor on multivariate analysis for all-cause mortality and cardiovascular death 229 
after adjusting for clinical variables (including age, sex, BMI, hypertension, smoking status, and 230 
diabetes) and biomarkers.7 Soluble ST2 within the normal range had prognostic value additive 231 
to NT-proBNP and hs-cTnT, supporting its utility in a multimarker approach. Results of a 2 year 232 
follow-up from the ARTEMIS (international Ambulatory blood pressure Registry: TEleMonitoring 233 
of hypertension and cardiovascular rISk project) study, involving a study population of 1,243 234 
patients and 649 controls, revealed that in multivariate analysis only sST2 and hs-CRP 235 
predicted the primary endpoint of cardiac death or heart failure hospitalization in both diabetic 236 
and nondiabetic patients with CAD.90 Results of the KAROLA study showed that after 237 
multivariable adjustments sST2 levels in a cohort of 1081 stable CAD patients independently 238 
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predicted both short-term (4.5 years) and long-term (12.3 years) risk for total mortality, and 239 
short-term risk for fatal cardiovascular disease-related events, but not non-fatal cardiovascular 240 
events.91   241 
Circulating sST2 levels have diagnostic and prognostic value after STEMI. sST2 levels 242 
measured within 1 day post-MI correlated positively with peak creatinine kinase, an estimate of 243 
the extent of necrosis, and negatively with pre-discharge left ventricular ejection fraction 244 
(LVEF).92, 93 Early sST2 positively correlated with infarct size and expansion, as well as greater 245 
infarct transmurality and endocardial extent, microvascular obstruction, and plasma aldosterone 246 
levels.94 Early values were a significant predictor of cardiovascular death and heart failure over 247 
the following 30 days after STEMI, independent of baseline characteristics or NT-proBNP levels 248 
and, in combination with NT-proBNP, improved risk stratification.93, 95 Interestingly, unlike NT-249 
proBNP, sST2 levels on presentation were not associated with clinical conditions linked to 250 
increased LV wall stress, such as age, hypertension, previous MI, or prior MI; however, higher 251 
levels were associated with diabetes mellitus.93   252 
In a recent report on multimarker risk stratification for STEMI involving upwards of 1258 253 
patients enrolled in the Clopidogrel as Adjunctive Reperfusion Therapy-­‐Thrombolysis in 254 
Myocardial Infarction 28 (CLARITY-­‐TIMI 28) trial, sST2 was a significant predictor of heart 255 
failure or short-­‐term cardiovascular death (out to 30 days) along with two other biomarkers, 256 
troponin T and myeloperoxidase (MPO).96 Soluble ST2 had greater prognostic value than hs-257 
cTnI for 30 day cardiac mortality in both STEMI and NSTEMI patients.97 Another study showed 258 
that elevated sST2 levels with STEMI were associated with increased all-cause mortality up to 1 259 
year and improved risk stratification using a multi-marker approach.98   260 
sST2 levels were reported to be elevated in patients with STEMI and NSTEMI, with 261 
levels markedly higher in those with STEMI. 88 In addition, the highest quintile of sST2 predicted 262 
mortality in patients with STEMI, but not those with NSTEMI. Others reported that elevated 263 
sST2 predicated long-term major adverse event in NSTEMI patients, but did not improve risk 264 
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stratification for established markers.99 In a recent study of 1401 first-ever MI patients involving 265 
mostly (79%) NSTEMI, higher sST2 values were associated with increased risk of death and 266 
heart failure over a 5 year follow-up, independent of other prognostic indicators. In this study, 267 
higher values of sST2 were associated with age, female sex, and hypertension, in addition to 268 
diabetes mellitus.100  Findings of a cross-sectional, population-based study revealed that sST2 269 
also positively correlates with markers of type 2 diabetes and endothelial dysfunction, but not 270 
established cardiovascular risk factors.10 This suggests that activated/stressed vascular 271 
endothelial cells are the source of sST2 in diabetes. While pathology-related increases in 272 
circulating sST2 have clinical value, others reported that sST2 levels in healthy men and women 273 
added little long-term predictive information for cardiovascular events or all-cause mortality.101 274 
Overall, there is strong evidence for the diagnostic and/or prognostic utility of sST2 in 275 
CAD and MI (both STEMI and NSTEMI), particularly in combination with established 276 
biomarkers. Key studies supporting this conclusion are listed in Table 2. The observation that 277 
circulating levels of IL-33 and sST2 exhibit an opposite pattern of change with increasing 278 
severity of CAD event, together with MI preclinical studies (see below), underpins the 279 
conclusion that enhancing cardiovascular activity of IL-33 may be beneficial for limiting 280 
cardiovascular events.   281 
 282 
Table 2. Utility of IL-33 and sST2 as biomarkers for cardiovascular diseases 283 
 284 
Diagnosis	   Biomarker	   Outcome/Prognosis	  
Coronary	  Artery	  
Disease	  (CAD)	  -­‐	  
General	  
IL-­‐33	  
Serum	  levels	  lower	  in	  patients	  with	  stable	  angina,	  and	  even	  
lower	  in	  patients	  with	  acute	  coronary	  syndrome	  (ACS)85	   
Elevated	  MMP-­‐28	  and	  decreased	  IL-­‐33	  in	  CAD	  patients	  
correlate	  with	  disease	  severity	  86	  
Differential	  IL-­‐33	  and	  IL-­‐6	  expression	  reported	  for	  those	  with	  
ACS	  or	  stable	  CAD87	  
No	  difference	  in	  those	  with	  ACS	  vs.	  stable	  CAD,	  although	  
highest	  quintile	  predicted	  mortality	  in	  patients	  with	  STEMI	  88	  
	  
	  
Increased	  levels	  in	  patients	  with	  ACS	  vs.	  patients	  with	  stable	  
CAD	  and	  normal	  controls	  88	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sST2	   sST2	  not	  correlated	  with	  stable	  CAD	  severity,	  but	  higher	  
levels	  independent	  predictor	  for	  all-­‐cause	  mortality	  and	  
cardiovascular	  death	  7 
Only	  sST2	  and	  hs-­‐CRP	  predicted	  cardiac	  death	  or	  heart	  
failure	  hospitalization	  in	  both	  diabetics	  and	  nondiabetics	  
with	  CAD90	  	  
Higher	  levels	  independently	  predicted	  short-­‐	  and	  long-­‐term	  
risks	  for	  total	  mortality,	  and	  short-­‐term	  risk	  for	  fatal	  
cardiovascular	  events91	  
Higher	  levels	  associated	  with	  increased	  all-­‐cause	  and	  
cardiovascular	  mortality102	  
STEMI	   sST2	  
Levels	  correlated	  positively	  with	  	  heart	  damage92,	  93	  	  
Positively	  correlated	  with	  infarct	  size	  and	  expansion,	  as	  well	  
as	  greater	  infarct	  transmurality	  and	  endocardial	  extent,	  
microvascular	  obstruction,	  and	  plasma	  aldosterone	  94	  	  
Early	  values	  predict	  increased	  mortality	  and	  heart	  failure	  
over	  subsequent	  30	  days,	  independent	  of	  baseline	  
characteristics	  or	  NT-­‐proBNP	  levels;	  improved	  risk	  
stratification	  in	  combination	  with	  NT-­‐proBNP93,	  95	  
Predictor	  of	  heart	  failure	  or	  short-­‐term	  cardiovascular	  death	  
along	  with	  troponin	  T	  and	  MPO96	  	  
Greater	  prognostic	  value	  than	  hs-­‐cTnI	  for	  30	  day	  cardiac	  
mortality	  in	  both	  STEMI	  and	  NSTEMI	  patients	  97	  	  
Elevated	  levels	  associated	  with	  increased	  all-­‐cause	  mortality	  
out	  to	  1	  year	  and	  improved	  risk	  stratification	  in	  multi-­‐marker	  
approach98	  	  
NSTEMI	   sST2	  
Elevated	  sST2	  predicated	  long-­‐term	  major	  adverse	  event	  but	  
did	  not	  improve	  risk	  stratification	  for	  established	  markers99	  
Elevated	  sST2	  associated	  with	  increased	  risk	  of	  death	  and	  
heart	  failure	  over	  next	  5	  years,	  independent	  of	  other	  
prognostic	  indicators;	  higher	  values	  associated	  with	  age,	  
female	  sex,	  hypertension,	  and	  diabetes100	  
Higher	  levels	  associated	  with	  adverse	  outcomes	  at	  30	  days	  
and	  1	  year;	  improved	  risk	  stratification	  in	  CVD	  and	  heart	  
failure	  at	  30	  days	  and	  1	  year	  when	  levels	  added	  to	  
established	  clinical	  biomarkers103	  
Elevated	  levels	  predict	  mortality	  at	  1	  year;	  independent	  of	  
CV	  comorbidities	  or	  risk	  factors	  such	  as	  age,	  renal	  function,	  
and	  diabetes104	  
Stroke	  
IL-­‐33	  
Elevated	  in	  acute	  ischemic	  stroke;	  lower	  levels	  associated	  
with	  greater	  stroke	  severity	  and	  large	  infarct;	  levels	  higher	  in	  
patients	  with	  favorable	  outcome;	  levels	  independent	  
predictor	  for	  functional	  outcome105	  
sST2	  
Higher	  sST2	  at	  admission	  associated	  with	  all-­‐cause	  mortality	  
90	  days	  after	  acute	  ischemic	  stroke,	  but	  no	  prognostic	  value	  
in	  multivariate	  analysis106	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Atherosclerosis	  
IL-­‐33	  
Increased	  expression	  in	  plaques;	  promotes	  leukocyte	  
adhesion	  to	  	  endothelial	  cells	  and	  induces	  adhesion	  
molecules	  and	  CCL2	  in	  endothelial	  cells	  107	  
Induces	  expression	  of	  CXCL1	  chemokine108	  
ST2L	   Similar	  	  ST2L	  expression	  in	  atherosclerotic	  plaques	  of	  
asymptomatic	  and	  symptomatic	  patients	  on	  T	  cells	  and	  
endothelial	  cells	  of	  neo-­‐angiogenic	  vessels;	  more	  ST2L	  in	  
macrophages	  of	  symptomatic	  patients109	  
sST2	  
Identified	  as	  risk	  factor	  for	  subclinical	  atherosclerosis;	  levels	  
positively	  correlated	  with	  standard	  atherosclerosis	  risk	  
factors	  110	  
Diabetes/Obesity	  
sST2	  
Blood	  levels	  positively	  associated	  with	  hypertension	  and	  
diabetes4	  
Levels	  correlate	  with	  markers	  of	  type	  2	  diabetes	  and	  
endothelial	  dysfunction,	  but	  not	  established	  cardiovascular	  
risk	  10	  
Levels	  elevated	  with	  obesity,	  suggesting	  attenuation	  of	  
beneficial	  actions	  of	  IL-­‐33	  in	  obesity	  111	  
Higher	  levels	  in	  type	  2	  diabetes	  4,	  10,	  112-­‐114	  
Positive	  association	  of	  levels	  with	  risk	  factors	  for	  diabetes	  
after	  adjusting	  for	  age	  and	  sex;	  highest	  increases	  	  associated	  
with	  increased	  risk	  for	  diabetes	  9	  
Association	  of	  hs-­‐TnT	  and	  sST2	  with	  cardiovascular	  and	  all-­‐
cause	  mortality	  during	  ~5	  year	  follow-­‐up	  among	  diabetics	  115	  
Levels	  among	  diabetics	  increased	  further	  by	  LV	  diastolic	  
dysfunction113,	  116	  
Association	  of	  severe	  obesity	  with	  increased	  expression	  in	  
endothelial	  cells	  of	  human	  adipose	  tissue111	  
Il-­‐33	  
Levels	  lower	  in	  non-­‐lean	  vs.	  lean	  individuals,	  and	  negatively	  
correlated	  with	  BMI	  and	  body	  weight	  in	  those	  lean	  and	  
overweight,	  but	  not	  obese;	  117	  negatively	  correlated	  with	  
HbA1c	  in	  non-­‐diabetic	  persons,	  and	  associated	  with	  
protective	  lipid	  profile	  
Severe	  obesity	  associated	  with	  increased	  expression	  in	  
endothelial	  cells	  of	  human	  adipose	  tissue	  111	  
 285 
 286 
Pathophysiological role of IL-33/ST2 signaling in preclinical studies of myocardial 287 
infarction  288 
The strong association between increased circulating levels of sST2 and poor prognosis 289 
in patients with MI provides circumstantial evidence for a protective role of IL-33 in the heart 290 
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under stress that is borne out by preclinical studies. Biomechanical strain induces expression of 291 
sST2 and IL-33 in both cardiac myocytes and fibroblasts, with cardiac fibroblasts being more 292 
responsive.118 Similarly, IL-33 was mostly expressed by interstitial cells (likely myofibroblasts) in 293 
pressure overloaded mouse hearts.118 Levels of IL-33 in human adult cardiac myocytes and 294 
fibroblasts are also increased by inflammatory cytokines.11 IL-33 was found to protect neonatal 295 
rat cardiomyocytes from cell hypoxia-induced caspase-3 cleavage and apoptosis, and this was 296 
associated with increased expression of anti-apoptotic proteins (XIAP, cIAP1, survivin, Bcl-xL, 297 
and Bcl-2).119 The addition of sST2 blocked these protective actions of IL-33. Others reported 298 
evidence for the attenuation of ROS generation by IL-33, and the subsequent sequential 299 
activation of PKCβII and JNK, in the protection of neonatal mouse cardiomyocytes from 300 
apoptosis after anoxia/reoxygenation.120  301 
In vivo preclinical evidence also indicates that IL-33 protects the heart from infarction. IL-302 
33 treatment was found to decrease fibrosis, infarct size, and apoptosis after ischemia-303 
reperfusion (I/R) in the rat and improve cardiac function.119 In addition, IL-33 reduced ventricular 304 
dilation, improved contractile function, and increased survival following coronary artery ligation 305 
in wild type, but not in ST2-/- mice.119 IL-33 treatment was associated with a decrease in mast 306 
cell density in the infarct area, as well as an increase in Th2 and decrease in Th1 genes in the 307 
infarct. Many of these beneficial actions of IL-33 are probably secondary effects on the 308 
myocardium, since as discussed IL-33 by itself may have pro-fibrotic actions. In addition, IL33 309 
activates mast cells and a reduction in cardiac mast cells was reported to attenuate myocardial 310 
contractility after MI.121 Thus, the reduction of mast cells in the study of Seki K et al.119 is 311 
probably secondary to general reduction of inflammation and unrelated to improved cardiac 312 
contractility. 313 
Another study on MI (permanent LAD occlusion) in mice also reported similar beneficial 314 
effects of post-treatment with IL-33 on cardiac function and structure, as well as reduced 315 
myocardial macrophage infiltration and inflammatory cytokine production, and suppression of 316 
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p38 MAPK and NF-κB activation.75  However, the exact involvement of p38 MAPK signaling in 317 
the cardioprotective actions of IL-33 is likely a matter of timing and model of injury. Others 318 
recently implicated activation of p38 MAPK in the anti-apoptosis and anti-inflammatory actions 319 
of pre-treatment with IL-33 in protecting the heart, including decreased expression of the 320 
cytokine/alarmin high mobility group box 1 protein (HMGB1), in a rat model of I/R-induced 321 
cardiac injury.122  322 
Diabetes mellitus increases the vulnerability of the heart to I/R-induced injury. This has 323 
been attributed in part to increased PKCβII activity, which is enhanced by diacylglycerol 324 
(DAG).123 Cellular levels of DAG are in turn regulated by DAG kinase (DGK), which catalyzes its 325 
conversion to phosphatidic acid. Diabetes-related exaggerated apoptosis and dysfunction of the 326 
myocardium that is observed with I/R was attributed to increased PKCβII activity due to reduced 327 
expression of DGK-zeta.123 The later was linked to reduced levels of IL-33, which was shown to 328 
induce DGK-zeta expression in the heart and isolated cardiomyocytes. Thus, IL-33 may 329 
negatively regulate PKCβII activity in cardiac myocytes both by attenuating oxidative stress and 330 
by enhancing expression of DGK-zeta. Evidence was reported that the reduced IL-33 levels in 331 
the diabetic heart result from high glucose-induced secretion of HMGB1 from cardiac 332 
myocytes.124 HMGB1 in turn stimulates TLR4 receptors on fibroblasts to reduce their IL-33 333 
production, thereby leading to enhanced collagen production and cardiac fibrosis. However, the 334 
means by which IL-33 suppresses fibrosis in the heart is not known and likely indirect. 335 
Surprisingly, IL-33 was found not to directly inhibit collagen I/III or periostin production by adult 336 
rat cardiac fibroblasts, or their proliferation; rather, IL-33 stimulated expression of cytokines and 337 
chemokines (IL-6 and CCL-2) associated with cardiac inflammation and fibrosis, although the 338 
migratory ability of the cardiac fibroblasts was attenuated.125 Interestingly, in a mouse infarction 339 
model, myocyte-targeted ablation of TGFβ signaling markedly augmented IL-33 expression in 340 
what appeared to be perivascular interstitial cells, but no impact on collagen deposition in the 341 
infarct was seen.126 342 
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In summary, despite the fact that stressed and injured cardiac myocytes may secrete IL-343 
33, they produce factors (e.g., HMGB1) that reduce IL-33 production by cardiac fibroblasts, 344 
which may favor ROS-induced PKCβII/JNK activation, inflammatory cytokine and apoptosis 345 
gene expression. Several rodent studies reported a protective effect of IL-33 supplementation 346 
on the heart, delivered either before or after MI, which is attributable to reduced ROS 347 
production. The cell type(s) mediating the cardioprotective effects of IL-33 is (are) not yet 348 
defined. Paradoxically, Abston et al.  have reported that IL-33 treatment in healthy mice induces 349 
inflammatory cytokines in the heart, and independently induces eosinophilic pericarditis and 350 
impairs heart function.127 Strain differences or dosing regimen cannot explain the discrepant 351 
findings between this study and the ones involving MI, so other factors such as diet, surgical 352 
procedure, pre-existing injury, need to be considered. In any event, the findings of Abston et al. 353 
caution against taking a broad approach in IL-33 delivery for protecting the infarcted heart.    354 
 355 
IL-33/ST2 signaling in the pathophysiology and clinical outcome of stroke 356 
In patients (n = 206) who suffered acute ischemic stroke, serum IL-33 levels were 357 
elevated; however, lower levels were associated with greater stroke severity and large infarction 358 
volume. Levels were higher in patients with a favorable outcome, and IL-33 levels were an 359 
independent predictor for functional outcome.105 On the other hand, higher sST2 at the time of 360 
admission was reported to be associated with all-cause mortality 90 days after acute ischemic 361 
stroke (n = 721), but did not offer prognostic value in multivariate analysis.106  Larger, 362 
adequately powered and well-designed studies across multiple centers with proper controls are 363 
needed to assess the prognostic value of IL-33/sST2 in ischemic stroke.    364 
In preclinical models, treatment with IL-33 was shown to be protective in ischemic 365 
stroke128, 129 and spinal cord injury130 by causing a shift towards the M2 microglial/macrophage 366 
cell phenotype and attenuating inflammation. Expression of IL-33 in oligodendrocytes and 367 
astrocytes increases with ischemic injury in the mouse, along with ST2L expression in microglia 368 
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and astrocytes. Yang et al.131 provided evidence that the neuroprotective actions of IL-33 in 369 
ischemic stroke are due in part to its stimulation of anti-inflammatory cytokine IL-10 production 370 
by microglia cells.  371 
In summary, despite serum IL-33 being increased in ischemic stroke, an association of 372 
lower IL-33 and higher sST2 with worse outcome was observed. Although based on a single 373 
study, this is consistent with the idea that in ischemic stroke IL-33 has protective actions that are 374 
dampened by sST2 (Table 2), as supported by animal studies. However, by themselves early 375 
serum IL-33 levels may reflect mostly the extent of injury, rather than serving as a measure of 376 
the extent of protection mounted. Paradoxically, its induced target sST2 is likely a gauge of both 377 
extent of injury and blockade of protection. For that reason and technical issues previously 378 
discussed, greater confidence ought to be placed in reported sST2 values in MI and stroke 379 
studies.     380 
 381 
Genetic variants in IL-33 and ST2 genes and relationship with CAD 382 
 A prospective study of 2,991 Framingham Offspring Cohort participants revealed that 383 
much of the variation in sST2 production among individuals is due to genetic factors.132 The 384 
IL1RL1 gene encodes for both the membrane-bound receptor isoform (ST2L) and the soluble 385 
protein (sST2) through alternative promoter activation and splicing.133 Multiple single-nucleotide 386 
polymorphisms (SNPs) within IL1RL1 were found to correlate with sST2 levels in a genome-387 
wide association study, and five missense variants mapping to the intracellular domain of ST2L, 388 
which is not present in sST2, correlated with higher sST2 levels.132 Experiments on cultured cell 389 
lines expressing the intracellular variants attributed the increase in sST2 levels to an autocrine 390 
loop of increased IL-33 induction and enhanced ST2L responsiveness. Briefly, increased sST2 391 
was ascribed to (a) increased induction of IL-33 by ST2L because of enhanced NF-κB and AP1 392 
signaling, which also selectively activated the proximal promoter of IL1RL1 linked to sST2 393 
expression, and (b) a selective increase in ST2L expression due to an increase in endogenous 394 
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IL-1β levels resulting from enhanced constitutive ST2L-mediated inhibition of a 395 
counterregulatory PI3K/AKT/mTOR signaling axis that attenuates IL-1β levels. In light of the 396 
recently reported outcome of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study 397 
(CANTOS), 134, 135 the potential synergistic interplay between IL-1β and IL-33 in vivo merits 398 
investigation.   399 
An earlier study linked two polymorphisms in the distal promoter of IL1RL1 that drives 400 
ST2L expression to enhanced CAD severity, but no sST2 measurements were made.136 401 
Another SNP in IL1RL1 was linked to increased risk for CAD without defining its functional 402 
impact.137 Yet another SNP of IL1RL1 was associated with lower circulating sST2 levels; 403 
however, in affected individuals with CAD or peripheral artery disease, increased sST2 levels 404 
were an independent predictor of all-cause mortality by multivariable Cox regression analysis, 405 
but not for secondary endpoints of CV death, MI, hospitalization for heart failure, stroke, and 406 
amputation.138 Unfortunately, the impact of this SNP on IL-33 levels or ST2L expression was not 407 
determined. An SNP within the promoter region of the IL-33 gene was associated with 408 
increased circulating levels of IL-33 and increased risk for CAD.137 Another IL-33 gene 409 
polymorphism that was linked to decreased IL-33 production was associated with a decreased 410 
risk for developing premature CAD or central obesity.139 Others reported the opposite effect of 411 
this SNP genotype on serum IL-33 levels in patients with rheumatoid arthritis and thus no causal 412 
relationship can be drawn.140 In addition, a direct causal relationship between IL-33 levels and 413 
CAD is not established as neither of the studies on IL-33 gene variants reported values of sST2. 414 
Nonetheless, an SNP in the IL-1RAcP gene was also linked to CAD risk.141  415 
 In summary, limited reports suggest that genetic variants in or around the IL1RL1 gene 416 
are associated with differences in expression levels of both sST2 and ST2L, as well as IL-33. 417 
Polymorphisms in the gene cluster within which IL1RL1 resides have been associated with a 418 
number of immune and inflammatory conditions,132 but more extensive GWAS are needed to 419 
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establish a causal link between IL1RL1 variants and CAD. This is the case for the IL-33 gene as 420 
well. 421 
 422 
Mechanistic insights into the role of IL-33/sST2 in atherosclerosis  423 
 Increased IL-33 expression has been detected in human atherosclerotic plaques, 424 
emphasizing the importance of IL-33 in vascular biology and remodeling (Fig. 3).107 425 
Atherosclerosis is characterized by a chronic arterial wall inflammation that plays a major role in 426 
atheroma formation.142 The presence of oxidized low-density lipoproteins (ox-LDL) in the vessel 427 
induces the production of pro-inflammatory mediators like cytokines and growth factors from 428 
surrounding tissues that further fuel the inflammatory response and atherosclerosis 429 
progression.143 Miller at al. revealed that IL-33 administration to ApoE-/- model of atherosclerosis 430 
in mice, induced a shift from the Th1 pro-atherosclerotic immune response to a Th2 protective 431 
and pro-resolving immune response by significantly increasing Th2 cytokine production (IL-4, IL-432 
5 and IL-13) and decreasing IFNγ levels, a typical Th1 cytokine.144 Th1 to Th2 polarization 433 
resulted in a reduction of aortic atherosclerotic lesions when compared to vehicle-treated 434 
group.144 Of note, atherosclerotic plaque formation and progression is multifactorial and T cell 435 
infiltration can either increase (Th1) inflammation in plaques or decrease (Th2/Treg) it 436 
depending on the dominant phenotype.145 In addition to polarizing effects, IL-33 increased levels 437 
of atheroprotective natural IgM type anti-ox-LDL antibodies suggesting a potential effect on B1 438 
cells. Neutralizing IL-33 effects via sST2 administration to ApoE-/- mice resulted in aortic plaque 439 
expansion when compared to control IgG-treated group. Additionally, blocking IL-5 with a 440 
neutralizing antibody negated the protective effect of IL-33 and dampened the production of ox-441 
LDL antibodies suggesting that IL-5 might have a key role in the atheroprotective effect of IL-442 
33.144 In vitro studies on the other hand, showed that IL-33 atheroprotection might have 443 
occurred via inhibition of macrophage foam cell formation through decreased acetylated LDL 444 
and ox-LDL uptake and enhanced cholesterol efflux.146  Recently, the ability of IL-33 to protect 445 
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macrophage-derived foam cells from cholesterol overload was attributed to the induction of IL-446 
10, which helped IL-33 in an autocrine manner to increase expression of ATP-binding cassette 447 
transporter (ABCA1), potentially promoting cholesterol efflux.147  448 
Multiple lines of evidence support the concept that IL-33 may also be atheroprotective by 449 
engaging ILC2s and activating downstream type 2 immunity, mainly IL-5 and IL-13.148, 149 IL-5 450 
may stimulate B1 cell proliferation and production of atheroprotective natural IgM antibodies 451 
against the phosphorylcholine (PC) head group of oxidized phospholipids within LDL.149-151 452 
Besides inducing the expansion of ILC2s, recent evidence indicates that IL-33 promotes the 453 
egress of ILC2s from the bone marrow and possibly from secondary lymphoid organs,152 which 454 
further lends weight to the idea that administration of IL-33 at pharmacological levels may be 455 
necessary to reveal its role in atherosclerosis. Consistent with this possibility, loss of either 456 
endogenous IL-33 or its receptor ST2 was found to have no impact on development of 457 
atherosclerosis in ApoE-deficient mice.153 Activated ILC2s may also attenuate the progression 458 
of atherosclerosis by producing IL-13, which polarize macrophages towards the “M2” like 459 
phenotype.154 In addition, the actions of ILC2s in regulating adipose tissue homeostasis and 460 
limiting obesity (see Obesity and type 2 diabetes) may be an additional means by which IL-33 461 
exerts atheroprotective effects.   462 
IL-33 may also contribute to an increase in Treg cells, which exert anti-atherogenic 463 
effects by limiting both adaptive and innate immune responses.155-157 This function of IL-33 may 464 
be compromised in atherosclerosis due to both increased serum levels of sST2 and reduced 465 
levels of CD4+ST2+ cells.158 Recent evidence shows that expression of ST2 is also a feature of 466 
a sizable number of tissue-resident Treg cells that are important for tissue repair and promoting 467 
organ homeostasis.159 Their expansion and activation is stimulated by IL-33.159, 160 These ST2+ 468 
Tregs exert anti-inflammatory actions and suppress CD4 T cell proliferation through the release 469 
of IL-10 and TGF-β.161  This pool of Treg cells is especially prominent in visceral adipose tissue, 470 
where Treg cells support metabolic functions and possibly adipocyte differentiation.162, 163 471 
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 Little information is available concerning the expression pattern of the IL-33/ST2L axis 472 
within the atherosclerotic plaque. In an immunohistochemical study on endarterectomy samples, 473 
Marzullo et al.109 observed that ST2L was expressed in atherosclerotic plaques to a similar 474 
extent in asymptomatic and symptomatic patients on both T cells and endothelial cells of neo-475 
angiogenic vessels (much more so than the endothelial cells covering the residual lumen of the 476 
vessel). In contrast, expression of ST2L on macrophages was more remarkable in symptomatic 477 
patients. Based on these observations, the authors hypothesize that the IL-33/ST2L axis drives 478 
plaque development and eventual rupture; however, the sample size in their study was small, 479 
and causality was not studied. Others have recently suggested that IL-33 may contribute to 480 
plaque progression in part by inducing expression of the chemokine CXCL1 (see Vascular 481 
inflammation).108 On the other hand, in patients with primary hypertension, a major risk factor 482 
for atherosclerosis, circulating levels of sST2 were found to be high, whereas IL-33 levels were 483 
low.110 Moreover, sST2 was identified as a risk factor for subclinical atherosclerosis and its 484 
levels were positively correlated with the standard atherosclerosis risk factors, LDL cholesterol, 485 
C-reactive protein (CRP), and carotid intima-media thickness.110   486 
 The overall evidence supports the conclusion that IL-33 has atheroprotective effects. 487 
Several mechanisms may explain these actions. These include a shift in T cell polarization from 488 
Th1 to Th2 and an increase in Treg cells, increased levels of natural IgM anti-ox-LDL 489 
antibodies, inhibition of macrophage foam cell formation, stimulation of ILC2s, and polarization 490 
of macrophages towards the “M2” like phenotype. 491 
  492 
Vascular inflammation 493 
Several studies have reported direct pro-inflammatory effects of IL-33 on endothelial 494 
cells. For instance, IL-33 induces the secretion of the inflammatory cytokines IL-6 and IL-18 495 
from human umbilical vein endothelial cells (HUVECs),164 as well as the expression of 496 
chemoattractants for leukocytes (CXCL1 and CCL2).108 Also, IL-33 promotes the adhesion of 497 
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human leukocytes to human endothelial cells and induces vascular cell adhesion molecule-1, 498 
intercellular adhesion molecule-1, endothelial selectin, and CCL2 mRNA and protein expression 499 
in human coronary artery and umbilical vein endothelial cells in vitro and human explanted 500 
atherosclerotic plaques ex vivo.107 These effects of IL-33 on endothelial cells and immune cells 501 
may explain why increased IL-33 serum levels after coronary stent implantation are associated 502 
with coronary in-stent restenosis,165 as leukocyte activation is a critical step in development of 503 
restenosis after PCI.166 Interestingly, Pollheimer et al.167 observed that the pro-inflammatory 504 
actions of IL-33 on cultured HUVECs was greater in proliferating cells and correlated with ST2L 505 
receptor levels. Their observations are consistent with the previously mentioned findings of 506 
Marzullo et al.109 on endarterectomy samples of human carotid atherosclerotic plaques.  507 
Other studies have demonstrated that IL-33 promotes angiogenesis and vascular 508 
permeability in vitro and in vivo, notably within the context of inflammation.168-173 The pro-509 
inflammatory actions of IL-33 on the vasculature, and endothelial cells in particular, may 510 
contribute to the pathogenesis of giant-cell arteritis (GCA), which is an inflammatory disease of 511 
blood vessels that occurs in the elderly. The exact basis for GSA is uncertain, but ageing-512 
related alterations in the immune system in genetically predisposed individuals seem to be 513 
involved.174 Recently, increased expression of both IL-33 and ST2, chiefly in endothelial cells of 514 
newly formed vessels, was found in GCA arteries.175 IL-33 expression correlated with the 515 
degree of vessel wall inflammation and was reduced in arteries from steroid-treated GCA 516 
patients.  In addition, a positive association was observed between IL-33 and the numbers of 517 
neovessels, suggesting that IL-33 participates in the pathogenesis of angiogenesis-dependent 518 
inflammation in GCA. Although no Th2 cytokines were detectable, expression levels of IL-33 519 
correlated with the presence of M2 macrophages, the latter being reported to promote 520 
angiogenesis in vivo.176 Recently, the rs7025417 polymorphism in the IL-33 gene, which was 521 
noted to be associated with increased IL-33 plasma levels, was identified as a risk factor for 522 
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GCA in a large meta-analysis involving a total of 1,363 biopsy-proven GCA patients and 3,908 523 
healthy controls from four European cohorts.177  524 
 GCA and other inflammatory or infectious conditions increase the risk for having an 525 
acute aortic dissection. Other risk factors include hypertension, smoking, atherosclerosis, and 526 
certain genetic diseases. In a recent large retrospective study with a prospective validation 527 
cohort, sST2 was found to have overall superior diagnostic utility for detecting acute aortic 528 
dissection among emergency room patients with sudden-onset severe chest pain, which is 529 
easily misdiagnosed.178 This finding and those related to GSA and diabetes (see IL-33 and 530 
sST2 as biomarkers in coronary artery disease and myocardial infarction and Obesity 531 
and type 2 diabetes) highlight the utility of IL-33/sST2 as a biomarker of vascular health. 532 
In summary, IL-33 has been implicated in vascular inflammation via upregulation of 533 
adhesion molecules and chemokines for leukocytes. The pro-inflammatory actions of IL-33 on 534 
endothelial cells contribute to the pathogenesis of GCA, and are seemingly more prominent in 535 
angiogenesis. Further studies are needed to establish the role IL-33-induced endothelial 536 
inflammation in restenosis, as well as plague and post-ischemic neoangiogenesis. 537 
  538 
Obesity and type 2 diabetes  539 
 Obesity and its common consequence, type 2 diabetes are major risk factors for 540 
cardiovascular disease that are marked by chronic systemic and vascular inflammation. 179, 180 541 
Obese adipose tissue is characterized by an inflammatory immune environment consisting of 542 
classically activated M1 macrophages, cytotoxic T cells, and pro-inflammatory Th1-type 543 
cytokines (such as, TNF-α and IFN-γ).181 In contrast, lean fat tissue is characterized by an anti-544 
inflammatory environment of alternatively activated M2 macrophages, eosinophils, Th2 cells, 545 
Tregs, and ILC2s, along with anti-inflammatory Th2-type cytokines (such as, IL-4, IL-5, IL-9, and 546 
Il-13). IL-33 was recently shown to regulate white adipose tissue (WAT) homeostasis, a process 547 
that when dysregulated results progressively in the pro-inflammatory state, obesity, insulin 548 
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resistance, and the metabolic syndrome.77 Production of IL-33 by WAT is stimulated by the 549 
sympathetic nervous system, with IL-33 exerting positive reinforcement by inducing the 550 
upregulation of tyrosine hydroxylase, a rate-limiting enzyme in catecholamine biosynthesis.182 551 
Compared to wild type mice fed a high fat diet, ST2 knockout mice fed a high fat diet have a 552 
higher body weight and greater fat mass, along with more impaired insulin secretion and 553 
glucose tolerance.183 The major orchestrators in the actions of IL-33 on adipocyte function and 554 
metabolic homeostasis in both rodents and humans are ILC2s, which may actually be the major 555 
source of the type 2 cytokines in WAT, rather than Th2 cells.184, 185 IL-33 that is released most 556 
likely by adipose tissue endothelial cells, and perhaps adipocytes themselves, maintains ILC2 557 
cells in WAT and stimulates them to initiate a number of actions that limit adiposity by increasing 558 
caloric expenditure.77, 185, 186 The overall process is known as beiging or browning of WAT and 559 
involves upregulation of uncoupling protein 1 (Ucp-1) in adipocytes.77 ILC2 cells were proposed 560 
to recruit eosinophils and M2 macrophages, which support optimal beiging of WAT through the 561 
release of type 2 cytokines. ILC2 cells also produce methionine-enkephalin peptides that 562 
directly act on adipocytes to promote beiging.184 IL-33 may also exert positive regulatory actions 563 
on WAT mass and milieu via the development and maintenance of ST2+ visceral adipose 564 
tissue-Treg cells, which are diminished in obese mice and implicated in preserving insulin 565 
sensitivity and glucose tolerance through dampening actions on pro-inflammatory M1 566 
macrophages and CD8+ T cells.162  On the other hand, while M1 macrophage-driven 567 
inflammation subserves obesity-associated insulin resistance, fat-resident ST2+ Treg cells have 568 
been implicated in promoting age-associated insulin resistance.187 One possible explanation 569 
would be that some degree of inflammation is favorable for adipose tissue remodeling and 570 
metabolic function.    571 
 Serum IL-33 levels are lower in non-lean individuals compared to those who are lean, 572 
and negatively correlated with BMI and body weight in those who are lean and overweight, but 573 
not obese.117 In addition, IL-33 was found to be negatively correlated with HbA1c in non-diabetic 574 
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persons, but not diabetics, and to be associated with a protective lipid profile. On the other 575 
hand, severe obesity is associated with increased expression of both IL-33 and ST2 in 576 
endothelial cells of adipose tissue of both humans and mice, although the significance of this 577 
observation to endothelial function or inflammation is unclear.111 Plasma sST2 levels are also 578 
reported to be elevated with obesity in humans, suggesting an attenuation of the beneficial 579 
actions of IL-33 in obesity.111  Several studies report higher circulating sST2 levels in individuals 580 
with type 2 diabetes.4, 10, 112-114 A recent study reported a positive association between sST2 581 
levels and various risk factors for developing diabetes after adjusting for age and sex and 582 
implicated the highest increases in sST2 with increased risk for developing diabetes.9 Among 583 
diabetic patients, only hs-TnT and sST2 were found to be independently associated with 584 
cardiovascular and all-cause mortality during a ~5 year follow-up.115 Levels of sST2 among 585 
diabetics are increased further by LV diastolic dysfunction.113, 116  586 
In summary, IL-33 has been shown to limit adiposity by increasing caloric expenditure 587 
via ILC2s and prevents insulin resistance and impaired glucose tolerance by taming WAT 588 
inflammation via WAT Tregs. Plasma sST2 levels are increased with obesity and are a risk 589 
factor for development of type 2 diabetes. Increased circulating sST2 in type 2 diabetes may be 590 
reflective of microvascular endothelial inflammation. 591 
 592 
Unresolved issues and future directions 593 
Accumulating evidence supports the conclusion that sST2 is a biomarker of vascular 594 
health with diagnostic and/or prognostic value in various cardiovascular diseases, including 595 
coronary artery disease, myocardial infarction, atherosclerosis, giant-cell arteritis, acute aortic 596 
dissection, and ischemic stroke, as well as obesity and diabetes. However, the role of IL-33 is 597 
more complicated, as this alarmin may have both pro- and anti-inflammatory actions depending 598 
upon which cell type is engaged (Fig. 4). Overall, the actions of IL-33 in vivo are pleiotropic and 599 
must be viewed in pathophysiological context.   600 
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In pursuing the pharmacological potential of IL-33/ST2, it is important to acknowledge 601 
the detrimental versus protective effects of IL33/ST2 signaling. There is a need for additional 602 
experimental studies in various contexts to better comprehend the role of IL33/ST2 signaling. 603 
For example, the cell-specific effects of IL33 in vivo; the impact of the microbiota; the impact of 604 
acute injury (IL33 can be secreted after MI, and atherosclerosis can be accelerated after MI; 605 
does IL33/ST2 signaling play a distinct role in this context?), the interaction with other CV risk 606 
factors (does IL33/ST2 signaling affect atherosclerosis differently in obese or diabetic 607 
conditions?), etc. Additionally, there is a need for GWAS studies to address causality between 608 
IL33/ST2 signaling and CVD. To exploit the translational potential of IL-33/ST2-based therapies, 609 
a better understanding of differences in pharmacology between sST2 and anti-ST2 is needed.188 610 
Also, caution must be exercised in assessing the translational relevance of studies with injection 611 
of recombinant IL33, which might not reflect endogenous levels. Several strategies that aim at 612 
blocking IL33 signaling are nowadays feasible in patients. A few pharmaceutical companies are 613 
developing anti-IL33 mAb, anti-ST2, or sST2, mainly for asthma and COPD. Obviously, these 614 
approaches may lead to potential CV side effects; it might be wise to measure natural IgM anti-615 
oxLDL antibodies in these patients as the levels of those antibodies are inversely associated 616 
with CVD in humans. 617 
It is increasingly appreciated that the pathophysiological importance of IL-33 is highly 618 
dependent on cellular and temporal expression. The actions of IL-33 are likely to be pleiotropic 619 
in a dose-dependent manner, depending as well on which immune cells are activated and for 620 
how long or whether endothelial cells are engaged.  The final outcome would reflect the 621 
contribution of its protective and anti-inflammatory actions mediated by Treg cells, the 622 
inflammatory actions of various recruited immune cell types, and the injury-related response of 623 
stromal/parenchymal cells, all of which are modulated by the dampening actions exerted by 624 
sST2. In many cases, the levels of either ST2 or sST2 are positively affected by IL-33 in a dose-625 
dependent manner. IL-33 may also increase levels of myeloid-derived suppressor cells (MDSC), 626 
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which potently suppress T cell responses.189 Additional in vivo studies involving immune cell 627 
type-specific knockouts and transgenics are desired to better define the role of IL-33/ST2 axis in 628 
various diseases.  629 
The importance of spatiotemporal context in IL-33 signaling is illustrated by the actions 630 
of IL-33 on mast cells in asthma. On the one hand, IL-3 acts on mast cells via ST2 to increase 631 
bronchial hyperresponsiveness in part by boasting FcR-mediated degranulation.190 The 632 
released proteases generate forms of IL-33 with increased biological activity, thus establishing a 633 
positive feedback loop. On the other hand, mast cell sST2, which dampens the actions of IL-634 
33,2  is strongly induced by IL-33, and long-term exposure to IL-33 also induces a mast cell 635 
phenotype with decreased degranulation. Moreover, recent evidence shows that in smaller 636 
peripheral airways IL-33 protects against bronchial hyperresponsiveness by inducing PGE2 637 
formation by mast cells, which has relaxing effects on airway smooth muscle and anti-638 
inflammatory actions on mast cells.191  639 
 While ST2/IL-33 signaling in ILC2s, Tregs, and IL-10 producing B cells protects against 640 
inflammation, IL-33 clearly contributes to pathogenesis as a regulator of a type 2 immune 641 
response in certain settings (e.g., allergic diseases and asthma). Although initially beneficial in 642 
dealing with certain pathogens, chronic, excessive, or dysregulated type 2 immunity may 643 
contribute to tissue damage and fibrosis.13 As an early component of tissue injury and 644 
inflammation, IL-33 plays an important role in tissue repair, but in certain cases, IL-33 may 645 
contribute to excessive acute sterile inflammation and tissue damage. For instance, IL-33 from 646 
liver sinusoidal endothelial cells was found to exacerbate I/R-induced hepatic sterile 647 
inflammation, a contributor to organ damage in liver surgeries, by stimulating neutrophil 648 
extracellular trap formation.192 Moreover, ST2 expression by neutrophils was markedly 649 
increased by IL-33, thereby amplifying its inflammatory actions.  Both the identity of the cell type 650 
engaged and the magnitude of its response will impact on the outcome seen with IL-33.   651 
Unrecognized until recently are the different potencies of the various proteolytic forms of 652 
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extracellular IL-33 that are generated in vivo. Which forms are actually elevated in various 653 
disease conditions is largely unknown. There are great gaps also in our understanding of the 654 
nuclear roles of IL-33 and how these are coordinated with its extracellular actions. The 655 
processes involved in the secretion of IL-33 are also poorly understood. Finally, the potential 656 
actions of sST2 on its own, independent of its role as an IL-33 decoy receptor, need to be better 657 
established. 658 
In conclusion, IL-33 serves as an important local link between tissue injury or metabolic 659 
disturbances and a physiological response of limiting or repairing tissue damage. In CVD, IL-33 660 
exerts beneficial actions that are attenuated by its sST2 decoy receptor, which in many cases is 661 
induced by IL-33 and can serve as a biomarker of tissue stress/damage. IL-33 supplementation 662 
is atheroprotective and may be beneficial in treating MI and ischemic stroke. IL-33 may also 663 
prevent obesity and type 2 diabetes by regulating lipid metabolism. The mechanisms behind 664 
these beneficial actions are not fully defined, but are now known to involve Treg, ILC2 cells, and 665 
type 2 immune responses.  On the other hand, IL-33 appears to drive endothelial inflammation 666 
and angiogenesis, which is relevant to metabolic syndrome, type 2 diabetes, and GSA.  667 
Moreover, as in several pro-inflammatory and auto-immune diseases, exuberant IL-33 signaling 668 
may cause tissue damage due to recruitment/activation of mast cells or eosinophils. Thus, a 669 
cellular or targeted approach is needed to exploit the beneficial therapeutic potential of IL-33 in 670 
CVD.   671 
 672 
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Figure Legends  1310 
Figure 1: Pro-IL-33 Processing:  Pro-IL-33 possesses three major domains including nuclear 1311 
domain, activation domain, and interleukin-1 like cytokine domain. Following expression, pro-IL-1312 
33 may be processed into three major forms: 1) Inactive forms, following cleavage by 1313 
caspases 3 and 7 at interleukin-1 like cytokine domain if the cell undergoes apoptosis, 2) 1314 
Regulator of transcription, following localization to the nucleus due to the presence of two 1315 
bipartite nuclear localization sequences in the nuclear domain, ubiquitination of IL-33 as well as 1316 
its association with chromatin via protein-protein interaction is implicated in its 1317 
activation/repression of transcription, and  3) Active forms, also known as cytokine or alarmin, 1318 
following cleavage by extracellular proteases including cathepsin G and elastase at the 1319 
activation domain after being released extracellularly in response to cellular necrosis or stress. 1320 
CBM; Chromatin Binding Motif, Ub; ubiquitination. 1321 
 1322 
Figure 2: IL-33 Effects Post-Activation and Release: Active IL-33 binds to sST2 and ST2L. 1323 
Upon binding to the decoy receptor sST2, the effects of IL-33 on the cardiovascular system are 1324 
neutralized or diminished, promoting use of sST2 as a prognostic biomarker. Binding to ST2L 1325 
receptor which together with the co-receptor IL-1R accessory protein (IL-1RAcP) recruits 1326 
MYD88, IRAK1, IRAK4, and TRAF6, followed by activation of multiple signaling pathways, 1327 
including ERK1/2, JNK, p38 MAPK, and NF-κB and subsequent activation and regulation of 1328 
transcription. Cytokines secretion, immunomodulation, cell proliferation, activation, and survival 1329 
contribute to observed effects of IL-33 on the cardiovascular system. IL-33 effects, although 1330 
mostly cardioprotective, vary depending on the disease state and cell type. IR; Insulin 1331 
Resistance, WAT; White Adipose Tissue, I/R; Ischemia/Reperfusion, T2D; Type II diabetes, 1332 
CAD; Coronary Artery Diseases; HF; Heart Failure, AS; Aortic Stenosis, ROS; Reactive Oxygen 1333 
Species, IBD; Inflammatory Bowel Disease, COPD; Chronic Obstructive Pulmonary Disease.  1334 
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Figure 3: Conflicting actions of IL-33 in atherosclerosis. IL-33 has a number of actions on 1336 
endothelial and immune cells that promote inflammation and atherosclerosis. In contrast, 1337 
evidence indicates that IL-33 can act on T cells, macrophages, and B cells to attenuate plaque 1338 
development and progression. A better understanding of the temporal and spatial/cellular 1339 
factors involved in regulating the actions of IL-33 is needed to reconcile its opposing actions in 1340 
atherosclerosis.  1341 
 1342 
Figure 4: Cell-type specific pro- and anti-inflammatory actions of IL-33.  IL-33 also increases 1343 
generation of sST2 by certain cells, which serves as a decoy receptor. Note that generalized 1344 
responses are highlighted, and in some cases an opposite response may be elicited such as 1345 
mast cell-induced bronchodilation in small airways. See text for additional details. 1346 
